Onemednet Corp. — Filing Summary
Filing identity: The supplied 10-Q is for Data Knights Acquisition Corp., a blank-check company, not OneMedNet Corp. It reports the quarter ended June 30, 2022 and was signed August 15, 2022. OneMedNet is identified as the proposed merger target.
Business context and transaction
Data Knights had not begun operating or generating revenue. Its activities were pursuing a business combination. On April 25, 2022, it entered into a merger agreement with OneMedNet Corporation; target shareholders would receive company securities with an aggregate value initially set at $200 million, subject to specified adjustments. The transaction remained subject to customary conditions, including approvals by both companies’ stockholders and a minimum of $5,000,001 in tangible net assets at closing.
The SPAC extended its combination deadline from May 11 to August 11, 2022, and subsequently, on August 10, extended it again to November 11, 2022. The sponsor deposited $1.15 million into the trust for the second extension.
Financial results and liquidity
- Revenue and margins: No operating revenue; the company reported no operating business. Profit margins are not meaningful.
- Net income: $949,937 for Q2 2022, versus $4,308,152 for Q2 2021. First-half 2022 net income was $3,145,445, versus $4,307,307 from inception through June 30, 2021. 2022 earnings primarily reflected noncash gains from revaluing warrant liabilities: $1,595,082 in Q2 and $4,357,722 for the first half.
- Operating costs: $794,495 in Q2 2022 and $1,404,680 for the first half, including franchise tax expense. Q2 2021 costs were $70,494.
- Cash flow: First-half operating cash use was $445,671. Financing provided $1.15 million from the extension loan, which was placed in the trust account. Cash at June 30 was $7,480.
- Assets and trust: Total assets were $118.67 million, including $118.66 million held in trust. Redeemable Class A shares were carried at $118.45 million.
- Liabilities and liquidity: Total liabilities were $6.83 million, including $1.15 million extension loan, $4.03 million deferred underwriting fee payable, $1.17 million current liabilities, and $493,946 warrant liabilities. Working capital deficit was $1,158,449. The filing reports no long-term operating debt.
- Equity: Stockholders’ deficit was $6.61 million. Warrant revaluation reduced the warrant liability from $4.85 million at year-end 2021 to $493,946 at June 30, 2022.
Changes, outlook, and risks
Compared with Q2 2021, Q2 2022 net income was lower, while operating costs rose substantially. The comparison is affected by large, noncash warrant fair-value gains in both periods. The trust balance increased from $117.32 million at December 31, 2021 to $118.66 million at June 30, 2022.
Management stated it intended to complete the OneMedNet combination by November 11, 2022, but cautioned that completion and financing were not assured. The company had only $7,480 of cash outside the trust and disclosed substantial doubt about its ability to continue as a going concern if it failed to complete a business combination by the deadline. Management said sponsor or affiliate working-capital loans might be available, but lenders were not obligated to provide them. If no combination were completed by the deadline, the company would wind up and redeem public shares from the trust, subject to applicable terms; warrants could expire worthless.
The filing cites possible adverse effects from COVID-19 and the Russia-Ukraine conflict, including effects on the transaction and availability or terms of financing. It reports no legal proceedings and no material changes to previously disclosed risk factors. Disclosure controls were assessed as effective at a reasonable-assurance level; management also described additional accounting procedures and ongoing efforts to remediate a material weakness related to equity accounting and prior financial-statement restatement.
Investor verification points
- Confirm the correct issuer: this filing is Data Knights Acquisition Corp.’s 10-Q, not an operating-company 10-Q for OneMedNet Corp.
- Check the final status and terms of the OneMedNet merger, including approvals, transaction adjustments, financing, and redemption levels.
- Verify the November 11, 2022 deadline, extension funding, and the company’s ability to meet working-capital needs.
- Distinguish reported net income from operating performance: warrant fair-value gains were a major, noncash earnings component.
- Review the material-weakness remediation and prior financial-statement restatement disclosures. The filing gives inconsistent merger-agreement timing in different sections; confirm the definitive agreement date against the referenced filings.